OKYO

+ Watchlist + Portfolio

OKYO Pharma Limited

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.51
52-Week Range: $1.34 – $3.20
Market Cap: $79.77M
P/E (TTM): —
EPS (TTM): -0.24
Dividend Yield: —

Advanced Metrics

Price/Book: 6.47
PEG Ratio: —
Return on Equity: -263.78%
Return on Assets: -43.10%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 2.43
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-2.10M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $58.65M

OKYO Income statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$6.34M	$8.24M	$2.25M	$1.81M
Operating Expenses	$13.19M	$15.75M	$7.09M	$8.50M
Operating Income	-$13.19M	-$15.75M	-$7.09M	-$8.50M
EBITDA	-$13.18M	-$15.75M	-$7.10M	-$8.47M
Pretax Income	-$13.28M	-$16.80M	-$7.97M	-$8.94M
Income Tax	-$12.20K	$22.42K	-$3.26M	$7.99K
Net Income	-$13.27M	-$16.83M	-$4.71M	-$8.95M
Diluted EPS	-0.61	-0.57	-0.12	-0.24
Diluted Shares	22.26M	29.34M	39.49M	37.36M

OKYO Balance Sheet statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Cash & Equivalents	$4.05M	$826.85K	$1.56M	$14.59M
Receivables	$980.08K	$580.94K	$1.89M	$170.67K
Current Assets	$5.20M	$1.54M	$3.68M	$20.97M
Total Assets	$5.20M	$1.54M	$3.68M	$20.98M
Current Liabilities	$7.26M	$7.42M	$9.23M	$8.64M
Total Debt	$2.22M	—	—	—
Total Liabilities	$7.26M	$7.42M	$9.23M	$8.64M
Retained Earnings	-$125.70M	-$142.52M	-$143.02M	-$151.97M
Shareholders' Equity	-$2.05M	-$5.88M	-$5.55M	$12.34M
Working Capital	-$2.06M	-$5.88M	-$5.55M	$12.33M

OKYO Cash Flow statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Operating Cash Flow	-$7.70M	-$9.49M	-$1.81M	-$5.94M
Capital Expenditure	-$5.92K	—	-$1.21K	-$6.08K
Free Cash Flow	-$7.70M	-$9.49M	-$1.81M	-$5.94M
Depreciation & Amortisation	$3.80K	$3.87K	$2.56K	$1.82K
Stock-Based Compensation	$1.29M	$1.12M	$734.99K	$1.61M
Investing Cash Flow	-$5.92K	$0.00	-$1.21K	-$6.01M
Financing Cash Flow	$9.32M	$6.21M	$2.66M	$25.02M
Net Change in Cash	$1.62M	-$3.28M	$843.60K	$13.08M

OKYO Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q3 2025	Q1 2026
Cash & Equivalents	$1.56M	$4.22M	$14.59M
Receivables	$1.89M	$23.41K	$170.67K
Current Assets	$3.68M	$4.64M	$20.97M
Total Assets	$3.68M	$4.64M	$20.98M
Current Liabilities	$9.23M	$8.06M	$8.64M
Total Debt	—	$185.79K	—
Total Liabilities	$9.23M	$8.06M	$8.64M
Retained Earnings	-$143.02M	-$145.61M	-$151.97M
Shareholders' Equity	-$5.55M	-$3.42M	$12.34M
Working Capital	-$5.55M	-$3.42M	$12.33M

Market Snapshot

About

OKYO Pharma Limited is a biotechnology company developing therapeutics for inflammatory eye diseases and chronic pain conditions. The company focuses on novel formulations and delivery systems to address unmet medical needs in ophthalmology and inflammatory disorders.